CTMX (CytomX Therapeutics) LT-Debt-to-Total-Asset: 0.00 (As of Mar. 2026)

What is CytomX Therapeutics LT-Debt-to-Total-Asset?

CytomX Therapeutics CTMX +3.66% 36 LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus rates CTMX with a GF Score™ of 36/100 and a GF Value™ of $0.28 (Significantly Overvalued). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. CytomX Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.00.

CytomX Therapeutics's long-term debt to total assets ratio declined from Mar. 2025 (0.03) to Mar. 2026 (0.00). It may suggest that CytomX Therapeutics is progressively becoming less dependent on debt to grow their business.

CytomX Therapeutics (NAS:CTMX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

CytomX Therapeutics LT-Debt-to-Total-Asset Related Terms

CytomX Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for CytomX Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytomX Therapeutics LT-Debt-to-Total-Asset Chart

CytomX Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.05

0.04

0.00

CytomX Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.03	0.01	0.00	0.00	0.00

36GF Score

CytomX Therapeutics Inc CTMX

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

CytomX Therapeutics LT-Debt-to-Total-Asset Calculation

CytomX Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	0	/	151.566
	=	0.00

CytomX Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	0	/	359.358
	=	0.00

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.00 mean?

CytomX Therapeutics (CTMX) has a LT-Debt-to-Total-Asset of 0.00 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on CytomX Therapeutics and its competitors.

Is CytomX Therapeutics' LT-Debt-to-Total-Asset too high?

CytomX Therapeutics' current LT-Debt-to-Total-Asset is 0.00. Overall, CytomX Therapeutics has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does CytomX Therapeutics' LT-Debt-to-Total-Asset compare to SMNR and AURA?

CytomX Therapeutics' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on CytomX Therapeutics and its competitors. CytomX Therapeutics's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is CytomX Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, CytomX Therapeutics (CTMX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $3.38 — trading 1107.1% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. CytomX Therapeutics' overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For CytomX Therapeutics (CTMX), the current LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CytomX Therapeutics (CTMX) Overvalued in 2026?

Based on GuruFocus' analysis, CytomX Therapeutics stock appears to be overvalued. The current stock price of $3.38 is trading 1107.1% above its estimated GF Value™ of $0.28. GuruFocus considers CytomX Therapeutics to be Significantly Overvalued.

Key valuation signals for CTMX:

LT-Debt-to-Total-Asset: 0.00
GF Value™: $0.28 vs. price of $3.38 (1107.1% above fair value)
GF Score™: 36/100 with 4 warning signs

No single metric tells the full story. See the CTMX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CytomX Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies SMNR AURA OMER PHAT GERN LBRX ODTX VOR RLMD ALLO VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges 6C1:Germany

Address 151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website https://www.cytomx.com

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

36GF Score

Get the complete analysis for CTMX

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.38

Price

$0.28

GF Value

View CTMX Analysis

See LT-Debt-to-Total-Asset data for all stocks →